Bionano GenomicsBNGO
About: Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
Employees: 344
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
155% more call options, than puts
Call options by funds: $51K | Put options by funds: $20K
3.23% less ownership
Funds ownership: 9.61% [Q2] → 6.38% (-3.23%) [Q3]
10% less funds holding
Funds holding: 58 [Q2] → 52 (-6) [Q3]
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
45% less capital invested
Capital invested by funds: $4.5M [Q2] → $2.48M (-$2.02M) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Scotiabank Sung Ji Nam 50% 1-year accuracy 10 / 20 met price target | 339%upside $1 | Sector Perform Downgraded | 28 Aug 2024 |
Financial journalist opinion
Based on 5 articles about BNGO published over the past 30 days
